{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-006716","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2022-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.484253+00:00","generated_at":"2026-06-23T05:58:49.311386+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Odyssey Health dissolves sports advisory board, provides concussion drug update: Phase I complete, Phase II planned","bullets":["Dissolved sports advisory board to eliminate distraction and maintain focus on drug development.","Phase I human trial completed; drug proven safe and well tolerated.","Company plans to initiate Phase II trial to evaluate efficacy and safety in concussed patients.","Company states it has never received government funding; drug development funded by accredited investors.","Intellectual property and rights to the drug purchased on March 1, 2021 from a third party."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-006716","json":"https://secwatch.observer/filing/0001683168-22-006716.json","markdown":"https://secwatch.observer/filing/0001683168-22-006716.md","text":"https://secwatch.observer/filing/0001683168-22-006716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822006716/0001683168-22-006716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822006716/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:58:49.311386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}